Well for starters IDT targets generics where there is little competition due to the difficulty in making them. They don't make 'Statins'. Their problems are less relataed to the fact that they make generics and more to do with process and their lack of efficiency in getting these specialist generics back into the US market. Hopefully this will shortly change. The tide has turned at IDT but only just turned and most have yet to notice...
Ann: Director Resignation - Mr R Shigeno, page-5
Add IDT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.010(8.33%) |
Mkt cap ! $55.87M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 12.0¢ | $31.31K | 252.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 376665 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 517053 | 6 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| IDT (ASX) Chart |